Your search for ESKD returned 9 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Brian Park, PharmD remove

Your search for ESKD returned 9 results

Sort Results:

Relevant Recent

Did you mean: esrd


Invokana Approved to Slow Progression of Diabetic Nephropathy in T2D Patients

The FDA has approved a new indication for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease, doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and diabetic nephropathy with albuminuria >300mg/day.